Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $91.18M rose 68.6% year over year, behind the +154.4% change in trailing-twelve-month research & development. Sequentially, it fell 16.1% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.

Context

  • Research & development amounted to 40.5% of revenue in FY2025, down 90.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +68.6% toward the trailing-twelve-month pace of +154.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$91.18M-16.1% QoQ
Last fiscal yearDec 2025
$388.53M+64.1% YoY
LTMJun 2026
$490.14M+154.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.6%——
1 year+64.1%——
3-year CAGR+16.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
388.53M USD
Year-over-year change
+64.1%
4-year CAGR
+17.3%

Research & Development vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +154.4% is the 2nd highest of 7, against a peer median of -1.9%.
  • Research & development amounts to 38.2% of revenue for MDGL, versus a peer median of 1976.9%.
MDGL Competitors
Research & Development for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$509.32M USD+227.9%+85.3%—
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$490.14M USD+154.4%+16.5%38.2%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$148.75M USD+4.1%+17.8%2088.9%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$114.57M USD+28.4%+7.1%572.9%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
ALTAltimmune, Inc.LTM Mar 2026$66.77M USD-12.8%-2.0%185483.3%
SGMTSagimet Biosciences Inc.LTM Mar 2026$30.71M USD-36.7%+16.2%—
Peer median (excluding MDGL) —-1.9%+13.8%1976.9%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.